Abstract: Graph isomorphism phenomenon has been identified since the 1930s, which was first addressed in the graph-theoretical field and was thoroughly studied as a critical topic of computer science.

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI. The news comes as tech ...

To “cure all diseases” someday, Isomorphic Labs is ready to begin human trials of its AI-designed drugs. Artificial intelligence has a terrible reputation among the general public for many reasons, ...

In April 2025, Isomorphic Labs raised a $600 million in its first-ever external funding round, led by Thrive Capital. Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. As Isomorphic Labs aims its artificial ...

Katie Palmer covers telehealth, clinical artificial intelligence, and the health data economy — with an emphasis on the impacts of digital health care for patients, providers, and businesses. You can ...

It is an extendable isomorphic log sending library written in TypeScript for javascript applications in nodejs and browsers for reporting data (logs) to remote log storages like SumoLogic, Loggly and ...

On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck. Google was investing in his startup. The ...

Stream NBC 5 for free, 24/7, wherever you are. On a rare sunny day in London at the Google DeepMind office, Colin Murdoch saw the bank deposit from his employer come through. It wasn't his paycheck.

Turns out AI can be used for more than Ghibli-ifying selfies. AI drug developer Isomorphic Labs raised $600 million in its first external funding round as hype builds around AI-powered biotech.

London-based Isomorphic Labs, an AI-focused drug design and development company, has raised $600M (nearly €555.44M) in its first external funding round. The round is led by Thrive Capital, with ...